TriSalus Life Sciences (TLSI) Profit After Tax (2021 - 2026)

TriSalus Life Sciences' Profit After Tax history runs 6 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• On a quarterly basis, Profit After Tax rose 114.83% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was -$27.3 million, a 0.36% change from a year earlier, with the FY2025 full-year figure at -$39.2 million, down 30.56% from the prior year.
• Profit After Tax improved to $1.5 million in Q1 2026 per TLSI's latest filing, from -$9.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at $1.5 million in Q1 2026 and bottomed at -$35.6 million in Q4 2023.
• The 5-year median for Profit After Tax is -$8.7 million (2022), against an average of -$10.3 million.
• Across the five-year window, Profit After Tax plunged 2390.78% in 2022 and soared 114.83% in 2026, its largest moves.
• Year by year, Profit After Tax stood at -$22.5 million in 2022, then slumped by 58.1% to -$35.6 million in 2023, then jumped by 71.64% to -$10.1 million in 2024, then advanced by 3.51% to -$9.8 million in 2025, then soared by 115.78% to $1.5 million in 2026.
• Per Business Quant, the three latest TLSI Profit After Tax figures stand at $1.5 million (Q1 2026), -$9.8 million (Q4 2025), and -$10.8 million (Q3 2025).